Anavex Life Sciences (AVXL) Net Income towards Common Stockholders (2016 - 2025)

Anavex Life Sciences (AVXL) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$2.6 billion in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 2990.0% year-over-year to -$2.6 billion; the trailing twelve-month figure through Dec 2025 stood at -$42.4 billion (down 36070.68% YoY), and the FY2025 full-year result was -$39.8 billion, down 92377.13% from the prior year.
• Net Income towards Common Stockholders rose to -$2.6 billion in Q4 2025, from -$39.7 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$8.2 million in Q1 2021 to a low of -$39.7 billion in Q3 2025.
• A 5-year average of -$2.1 billion and a median of -$12.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 33.53% in 2023 and slumped 338170.2% in 2025, its largest moves.
• Tracing AVXL's Net Income towards Common Stockholders over 5 years: stood at -$10.9 million in 2021, then dropped by 19.2% to -$13.0 million in 2022, then surged by 33.53% to -$8.6 million in 2023, then plunged by 859.17% to -$82.7 million in 2024, then tumbled by 2990.0% to -$2.6 billion in 2025.
• Business Quant data shows AVXL's Net Income towards Common Stockholders at -$2.6 billion in Q4 2025, -$39.7 billion in Q3 2025, and -$60.3 million in Q2 2025.